IL6 and COVID-19: In addition to the antibody against IL-6, a case series study reported that RANTES (chemokine ligand 5, CCL5)-specific antibody leronlimab clinically improved critically COVID-19 patients and reduced the elevated plasma IL-6 and RANTES 36.